Tenaya Therapeutics (TNYA) Leerink Global Healthcare Conference 2026 summary

Program updates and scientific insights

• Three clinical-stage programs are advancing: two gene therapies (TN-201, TN-401) and a small molecule HDAC6 inhibitor (TN-301), with recent data showing broad efficacy in multiple preclinical models, including DMD and cardiac conditions.

• TN-301 demonstrates a multimodal mechanism, offering anti-inflammatory, anti-fibrotic, and metabolic benefits, and shows superiority over pan-HDAC inhibitors without associated safety liabilities.

• The company is efficiently progressing these programs without impacting its cash runway, focusing on enabling studies and planning for proof-of-activity trials.

• Strategic flexibility is maintained, with ongoing exploration of partnerships for larger indications while retaining in-house focus on prioritized assets.

• The Alnylam partnership brings $10 million upfront, research reimbursement, and potential milestones exceeding $1.1 billion, expanding the pipeline into siRNA therapeutics.

Clinical development and regulatory strategy

• TN-201 gene therapy for HCM has shown promising early clinical data, with significant biomarker and hypertrophy improvements at low doses; further data from higher dose cohorts and longer follow-up are expected this year.

• Ongoing regulatory engagement aims to define approvable endpoints for both full and accelerated approval, leveraging precedents from comparable programs.

• The TN-401 program for PKP2-related arrhythmias is enrolling patients with higher disease severity, using a robust natural history dataset to inform endpoint selection and regulatory discussions.

• The company is closely monitoring competitor data and regulatory feedback to refine its own pivotal trial designs and maintain a competitive edge.

• Multiple proof-of-activity studies are planned, with capital allocation decisions to be revisited after key data readouts later this year.

Strategic outlook and investor sentiment

• The pipeline now includes gene therapies, a small molecule, and siRNA programs, creating multiple value drivers and future opportunities.

• Efficient capital management allows simultaneous advancement of several programs without increasing spend.

• Investor and market response has been positive, particularly following the Alnylam collaboration and TN-301 progress.

• The company anticipates a transformative year, with upcoming data and partnerships potentially reshaping its profile.

• Strategic decisions on partnering versus in-house development will be guided by emerging data and market opportunities.